SLC6A2 rs5569: Understanding Pharmacogenomic Associations
The rs5569 variant is a single nucleotide polymorphism located within the SLC6A2 gene, which encodes the norepinephrine transporter. Research has investigated whether this specific genetic variation influences how individuals respond to methylphenidate, a medication commonly used to treat attention-deficit/hyperactivity disorder (ADHD).
What each genotype means
Potential improved medication response
Research has suggested that individuals with this genotype may show an improved response to methylphenidate compared to those carrying the A allele. However, evidence remains mixed across studies, and this finding should not be used to guide clinical decisions without consulting your healthcare provider or pharmacist.
This is a common genotype, though exact frequencies vary significantly by ancestral background.
Intermediate response profile
This genotype represents a heterozygous state for the rs5569 variant. Studies on how this specific combination influences medication response have yielded inconsistent results, and it is unclear if it confers the same potential benefits or risks as the homozygous genotypes. Please discuss any concerns regarding medication efficacy with your clinician.
This is a common genotype found in many populations globally.
Potential reduced medication response
Some research has indicated that individuals with this genotype may experience a diminished response to methylphenidate compared to those with the G/G genotype. Because findings in this area are limited and sometimes contradictory, this information should be discussed with a medical professional before making any changes to your treatment plan.
This genotype is less common than the G/G or G/A genotypes in many studied populations.
What is the rs5569 Variant?
The rs5569 variant is a single nucleotide polymorphism (SNP) situated on chromosome 16 within the SLC6A2 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. For rs5569, the variation involves a change between the nucleotides cytosine (C) and guanine (G), or sometimes reported as an A allele depending on the strand orientation used in specific studies. Because this variant is located within a gene that plays a critical role in neurotransmitter regulation, researchers have long hypothesized that it might influence how the brain processes certain medications. It is important to note that while this variant is cataloged in major databases like dbSNP, its functional impact on protein structure or expression remains a subject of ongoing scientific inquiry rather than a definitive clinical marker.
The Role of the SLC6A2 Gene
The SLC6A2 gene provides instructions for creating the norepinephrine transporter (NET) protein. This protein is responsible for clearing norepinephrine—a chemical messenger in the brain—from the synaptic cleft, which is the space between nerve cells. By transporting norepinephrine back into the presynaptic neuron, the NET protein helps regulate the intensity and duration of nerve signals. Because norepinephrine is involved in attention, focus, and the body's stress response, the SLC6A2 gene is a primary target for medications used to treat conditions like ADHD. Methylphenidate, for instance, is believed to exert its therapeutic effects in part by inhibiting the reuptake of norepinephrine and dopamine. Consequently, variations in the SLC6A2 gene are studied to determine if they alter the efficiency of this transporter, potentially affecting how a patient responds to stimulant medications.
Research and Evidence Strength
The evidence linking rs5569 to methylphenidate response is currently considered limited. While some meta-analyses and individual studies have reported statistically significant associations between specific genotypes of rs5569 and the efficacy of methylphenidate in children with ADHD, these findings have not been consistently replicated across all populations. Other studies have reported marginal or non-significant results, highlighting the complexity of drug response, which is often influenced by multiple genes, environmental factors, and the specific clinical characteristics of the patient. Because the effect sizes observed in these studies are generally small, this variant is not currently used in routine clinical practice to guide medication selection or dosing. The scientific community emphasizes that pharmacogenomic associations require robust, large-scale validation before they can be considered reliable predictors for personalized medicine.
Interpreting Your Genetic Information
If you have access to your genetic data regarding rs5569, it is essential to understand that this information does not provide a diagnosis or a guaranteed prediction of how you will respond to any medication. Pharmacogenomics is a developing field, and the association between rs5569 and methylphenidate is not strong enough to serve as a standalone clinical tool. You should never use genetic test results to start, stop, or change the dosage of any prescribed medication. If you are curious about how your genetics might influence your treatment plan, the best course of action is to discuss this with your prescribing physician or a clinical pharmacist. They can evaluate your genetic information in the context of your overall health, medical history, and current treatment goals to ensure you receive the most appropriate and effective care.
How common is this variant?
The frequency of the rs5569 alleles is variable across different global populations, and there is no single universal frequency for the G/G genotype.
Frequently asked questions
Can I use rs5569 to predict if methylphenidate will work for me?
No. The evidence linking rs5569 to methylphenidate response is limited and inconsistent. It is not a reliable predictor for individual treatment outcomes.
Is rs5569 a diagnostic test for ADHD?
No. rs5569 is a genetic variant studied in the context of pharmacogenomics, not a diagnostic marker for ADHD. ADHD is diagnosed through clinical evaluation by a healthcare professional.
Should I change my medication based on my rs5569 genotype?
Absolutely not. You should never alter your medication regimen based on genetic test results. Always consult your doctor before making any changes to your treatment.
Where can I find more information about SLC6A2?
You can find reliable information about the SLC6A2 gene and its functions through resources like the NIH's MedlinePlus Genetics or the NCBI Gene database.
Sources & further reading
Educational information only, last refreshed 10/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5569?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC6A2
This variant, also known as -3081A>T, is a significant contributor to individual differences in response to methylphenidate administration.
The C/C genotype of this variant is associated with a poorer response to methylphenidate in patients with lower baseline ADHD severity scores.